EUVIMEDEUVIMED entdecken
Crossref

Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease

Federica Tavaglione iD, Valentina Flagiello, Francesca Terracciani, Paolo Gallo, Emma Capparelli, Chiara Spiezia, Antonio De Vincentis, Andrea Palermo iD, Sara Scriccia, Giovanni Galati, Nicola Napoli, Samuel J Daniels und 6 weitere

Diabetes/Metabolism Research and Reviews · 2024

DOI: 10.1002/dmrr.3787 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2024. Verfasst von Federica Tavaglione und 17 weiteren Autor:innen. Beteiligte Einrichtung: Research Unit of Clinical Medicine and Hepatology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver, Metabolic Diseases, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Ricerca Finalizzata Ministero della Salute, AstraZeneca Agreement for Research, Progetti di Ricerca di Rilevante Interesse Nazionale Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Given the increasing number of individuals developing metabolic dysfunction‐associated steatotic liver disease (MASLD) and the low rate of those with progressive liver disease, there is a pressing need to conceive affordable biomarkers to assess MASLD in general population settings. Herein, we aimed to investigate the performance of the ultrasound‐derived fat fraction (UDFF) for hepatic steatosis in high‐risk individuals.

Methods

A total of 302 Europeans with obesity, type 2 diabetes, or a clinical history of hepatic steatosis were included in the analyses. Clinical, laboratory, and imaging data were collected using standardized procedures during a single screening visit in Rome, Italy. Hepatic steatosis was defined by controlled attenuation parameter (CAP) or ultrasound‐based Hamaguchi's score. UDFF performance for hepatic steatosis was estimated by the area under the receiver operating characteristic curve (AUC).

Results

Overall, median (IQR) UDFF was 12% (7–20). UDFF was positively correlated with CAP ( ρ = 0.73, p < 0.0001) and Hamaguchi's score ( ρ = 0.79, p < 0.0001). Independent predictors of UDFF were circulating triglycerides, alanine aminotransferase (ALT), and ultrasound‐measured visceral adipose tissue (VAT). UDFF AUC was 0.89 (0.85–0.93) and 0.92 (0.88–0.95) for CAP‐ and ultrasound‐diagnosed hepatic steatosis, respectively. UDFF AUC for hepatic steatosis was higher than those of fatty liver index (FLI), hepatic steatosis index (HSI), CAP‐score (CAPS), and ALT ( p < 0.0001). Lower age, ALT, and VAT were associated with discordance between UDFF and ultrasound.

Conclusions

UDFF may be a simple and accurate imaging biomarker to assess hepatic steatosis and monitor changes in hepatic fat content over time or in response to therapeutic interventions beyond clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fatty LiverMetabolic DiseasesNon-alcoholic Fatty Liver DiseaseHumansLiverUltrasonographyROC CurveBiomarkers

Stichwörter der Autor:innen

NAFLDNASHabdominal ultrasoundcontrolled attenuation parameterfatty liverimaging biomarkers

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Research Unit of Clinical Medicine and Hepatology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Operative Unit of Clinical Medicine and Hepatology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Research Unit of Food Science and Human Nutrition, Department of Science and Technology for Sustainable Development and One Health, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Research Unit of Internal Medicine, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
  • Operative Unit of Internal Medicine, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Research Unit of Metabolic Bone and Thyroid Disorders, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.

ORCID-Profile: Federica Tavaglione, Andrea Palermo, Umberto Vespasiani-Gentilucci

Förderung

  • Ricerca Finalizzata Ministero della Salute
  • AstraZeneca Agreement for Research
  • Progetti di Ricerca di Rilevante Interesse Nazionale Ministero dell'Università e della Ricerca
  • Ministero della Salute
  • Ministero dell'Università e della Ricerca

Zitieren

APA

Tavaglione, F., Flagiello, V., Terracciani, F., Gallo, P., Capparelli, E., Spiezia, C., De Vincentis, A., Palermo, A., Scriccia, S., Galati, G., Napoli, N., Daniels, S. J., Blau, J. E., Carlsson, B., Khazrai, Y. M., Incalzi, R. A., Picardi, A., & Vespasiani-Gentilucci, U. (2024). Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3787

Vancouver

Tavaglione F, Flagiello V, Terracciani F, Gallo P, Capparelli E, Spiezia C, et al. Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease. Diabetes/Metabolism Research and Reviews. 2024. doi:10.1002/dmrr.3787

BibTeX
@article{Tavaglione2024,
  author = {Tavaglione, Federica and Flagiello, Valentina and Terracciani, Francesca and Gallo, Paolo and Capparelli, Emma and Spiezia, Chiara and De Vincentis, Antonio and Palermo, Andrea and Scriccia, Sara and Galati, Giovanni and Napoli, Nicola and Daniels, Samuel J and Blau, Jenny E and Carlsson, Björn and Khazrai, Yeganeh M and Incalzi, Raffaele Antonelli and Picardi, Antonio and Vespasiani-Gentilucci, Umberto},
  title = {Non‐invasive assessment of hepatic steatosis by ultrasound‐derived fat fraction in individuals at high‐risk for metabolic dysfunction‐associated steatotic liver disease},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2024},
  doi = {10.1002/dmrr.3787}
}
Kostenlos starten →